| Ryan Sabado Buenaventura, PHARMD | |
|
600 Az-95, Bullhead City, AZ 86429 | |
| (928) 754-3961 | |
| Not Available |
| Full Name | Ryan Sabado Buenaventura |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 600 Az-95, Bullhead City, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427826502 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | S026676 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Sabado Buenaventura, PHARMD 600 Az-95, Bullhead City, AZ 86429 Ph: () - | Ryan Sabado Buenaventura, PHARMD 600 Az-95, Bullhead City, AZ 86429 Ph: (928) 754-3961 |
News Archive
The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.
The history of the pharmaceutical industry is closely linked to the business practices of the combination and purchase of corporations. From the creation of the combined entity of Warner-Lambert in 1955, to the purchase of Warner-Lambert by Pfizer in 2000, to the recent acquisition of Wyeth, pharmaceutical and biotech companies have expanded their pipelines, portfolios, and sales forces through mergers and acquisitions (M&A).
Patient satisfaction ratings after surgery for spinal degenerative disease—especially in terms of reduced pain and disability—are a good indicator of the procedure's effectiveness, reports a study in the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
› Verified 7 days ago
Albertus Rinke, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2350 Miracle Mile, Bullhead City, AZ 86442 Phone: 928-758-2212 | |
Mr. Ernest Wilmoth Bristol Jr., ERNEST BRISTOL Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2360 Hiway 95, Bullhead City, AZ 86442 Phone: 928-763-5858 Fax: 928-763-0972 | |
Chol Pae, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2360 Highway 95, Bullhead City, AZ 86442 Phone: 928-763-5858 | |
Adenike Okoduwa, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2735 Silver Creek Rd, Bullhead City, AZ 86442 Phone: 928-763-0258 | |
Mr. Venkata Satya Bhupathiraju, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2360 Highway 95, Bullhead City, AZ 86442 Phone: 928-763-5858 | |
Scott Simpson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 600 Higway 95, Bullhead City, AZ 86429 Phone: 928-754-3961 | |
Tuan Dinh, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2580 Highway 95, Ste 106, Bullhead City, AZ 86442 Phone: 928-299-5070 Fax: 928-299-5071 |